A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate
PHASE1CompletedINTERVENTIONAL
Enrollment
75
Participants
Timeline
Start Date
March 31, 1994
Study Completion Date
March 31, 2000
Conditions
Prostatic Neoplasms
Interventions
BIOLOGICAL
PROSTVAC
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001382 - A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate | Biotech Hunter | Biotech Hunter